Roger D Kouyos

List of Publications by Year
in descending order

206 papers	5,863 citations	81743 39 h-index	118652 62 g-index
234 all docs	234 docs citations	234 times ranked	7216 citing authors

#	Article	IF	Citations
1	Population biological principles of drug-resistance evolution in infectious diseases. Lancet Infectious Diseases, The, 2011, 11, 236-247.	4.6	220
2	Estimating the Basic Reproductive Number from Viral Sequence Data. Molecular Biology and Evolution, 2012, 29, 347-357.	3.5	206
3	Molecular Epidemiology Reveals Longâ€Term Changes in HIV Type 1 Subtype B Transmission in Switzerland. Journal of Infectious Diseases, 2010, 201, 1488-1497.	1.9	172
4	Epistasis between deleterious mutations and the evolution of recombination. Trends in Ecology and Evolution, 2007, 22, 308-315.	4.2	143
5	The state of affairs in the kingdom of the Red Queen. Trends in Ecology and Evolution, 2008, 23, 439-445.	4.2	135
6	Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 20509-20513.	3.3	133
7	Determinants of HIV-1 broadly neutralizing antibody induction. Nature Medicine, 2016, 22, 1260-1267.	15.2	133
8	Ambiguous Nucleotide Calls From Population-based Sequencing of HIV-1 are a Marker for Viral Diversity and the Age of Infection. Clinical Infectious Diseases, 2011, 52, 532-539.	2.9	127
9	Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART. Nature Communications, 2019, 10, 3193.	5.8	112
10	Phylogenetic Approach Reveals That Virus Genotype Largely Determines HIV Set-Point Viral Load. PLoS Pathogens, 2010, 6, e1001123.	2.1	108
11	Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European caseâ€“control study using centralized ultrasensitive 454 pyrosequencing. Journal of Antimicrobial Chemotherapy, 2015, 70, 930-940.	1.3	102
12	Exploring the Complexity of the HIV-1 Fitness Landscape. PLoS Genetics, 2012, 8, e1002551.	1.5	100
13	Prolonged persistence of measles virus RNA is characteristic of primary infection dynamics. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14989-14994.	3.3	99
14	Stochastic or deterministic: what is the effective population size of HIV-1?. Trends in Microbiology, 2006, 14, 507-511.	3.5	90
15	Cycling Empirical Antibiotic Therapy in Hospitals: Meta-Analysis and Models. PLoS Pathogens, 2014, 10, e1004225.	2.1	87
16	Inferring Epidemic Contact Structure from Phylogenetic Trees. PLoS Computational Biology, 2012, 8, e1002413.	1.5	85
17	Hepatitis C virus transmission among human immunodeficiency virusâ€infected men who have sex with men: Modeling the effect of behavioral and treatment interventions. Hepatology, 2016, 64, 1856-1869.	3.6	82
18	The path of least resistance: aggressive or moderate treatment?. Proceedings of the Royal Society B: Biological Sciences, 2014, 281, 20140566.	1.2	79

#	Article	IF	Citations
19	Bottleneck-induced transitions in a minimal model for intracellular transport. Physical Review E, 2006, 74, 031906.	0.8	76
20	Treatment-Naive Individuals Are the Major Source of Transmitted HIV-1 Drug Resistance in Men Who Have Sex With Men in the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2014, 58, 285-294.	2.9	75
21	The Role of Migration and Domestic Transmission in the Spread of HIV-1 Non-B Subtypes in Switzerland. Journal of Infectious Diseases, 2011, 204, 1095-1103.	1.9	74
22	Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). International Journal of Epidemiology, 2022, 51, 33-34j.	0.9	69
23	Persistence of Transmitted HIV-1 Drug Resistance Mutations Associated with Fitness Costs and Viral Genetic Backgrounds. PLoS Pathogens, 2015, 11, e1004722.	2.1	68
24	Frequency and Spectrum of Unexpected Clinical Manifestations of Primary HIV-1 Infection. Clinical Infectious Diseases, 2015, 61, 1013-1021.	2.9	67
25	RAPID PARASITE ADAPTATION DRIVES SELECTION FOR HIGH RECOMBINATION RATES. Evolution; International Journal of Organic Evolution, 2008, 62, 295-300.	1.1	65
26	Easy and accurate reconstruction of whole HIV genomes from short-read sequence data with shiver. Virus Evolution, 2018, 4, vey007.	2.2	64
27	Hospital-Community Interactions Foster Coexistence between Methicillin-Resistant Strains of Staphylococcus aureus. PLoS Pathogens, 2013, 9, e1003134.	2.1	61
28	Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. Journal of Infectious Diseases, 2015, 212, 28-38.	1.9	61
29	HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2016, 62, 115-122.	2.9	60
30	Can we believe the DAGs? A comment on the relationship between causal DAGs and mechanisms. Statistical Methods in Medical Research, 2016, 25, 2294-2314.	0.7	53
31	Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics. PLoS Pathogens, 2018, 14, e1006895.	2.1	53
32	Reasons for late presentation to HIV care in Switzerland. Journal of the International AIDS Society, 2015, 18, 20317.	1.2	52
33	Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis. Clinical Infectious Diseases, 2016, 62, 1310-1317.	2.9	52
34	Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smokingâ€"A modelling study. Lung Cancer, 2018, 121, 61-69.	0.9	49
35	Effect of Varying Epistasis on the Evolution of Recombination. Genetics, 2006, 173, 589-597.	1.2	48
36	Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 2016, 214, 399-402.	1.9	47

#	Article	IF	Citations
37	Tracing HIV-1 strains that imprint broadly neutralizing antibody responses. Nature, 2018, 561, 406-410.	13.7	47
38	A Treatment-as-Prevention Trial to Eliminate Hepatitis C Among Men Who Have Sex With Men Living With Human Immunodeficiency Virus (HIV) in the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2021, 73, e2194-e2202.	2.9	47
39	High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013. Journal of Hepatology, 2015, 63, 573-580.	1.8	46
40	Chemsex drugs on the rise: a longitudinal analysis of the Swiss HIV Cohort Study from 2007 to 2017. HIV Medicine, 2020, 21, 228-239.	1.0	46
41	Informed Switching Strongly Decreases the Prevalence of Antibiotic Resistance in Hospital Wards. PLoS Computational Biology, 2011, 7, e1001094.	1.5	45
42	Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs. Retrovirology, 2016, 13, 62.	0.9	45
43	Recombination Accelerates Adaptation on a Large-Scale Empirical Fitness Landscape in HIV-1. PLoS Genetics, 2014, 10, e1004439.	1.5	41
44	A highly virulent variant of HIV-1 circulating in the Netherlands. Science, 2022, 375, 540-545.	6.0	39
45	Five challenges in evolution and infectious diseases. Epidemics, 2015, 10, 40-44.	1.5	38
46	Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe. PLoS Biology, 2017, 15, e2001855.	2.6	38
47	Assessing Predicted HIV-1 Replicative Capacity in a Clinical Setting. PLoS Pathogens, 2011, 7, e1002321.	2.1	37
48	High Rates of Subsequent Asymptomatic Sexually Transmitted Infections and Risky Sexual Behavior in Patients Initially Presenting With Primary Human Immunodeficiency Virus-1 Infection. Clinical Infectious Diseases, 2018, 66, 735-742.	2.9	37
49	Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity. Molecular Biology and Evolution, 2018, 35, 27-37.	3.5	37
50	The Red Queen and the persistence of linkage-disequilibrium oscillations in finite and infinite populations. BMC Evolutionary Biology, 2007, 7, 211.	3.2	36
51	Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV. International Journal of Epidemiology, 2014, 43, 887-896.	0.9	36
52	The potential impact of coinfection on antimicrobial chemotherapy and drug resistance. Trends in Microbiology, 2015, 23, 537-544.	3.5	36
53	Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals. Medicine (United States), 2017, 96, e5849.	0.4	36
54	Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity. Nature Communications, 2021, 12, 6703.	5.8	36

#	Article	IF	Citations
55	An Integrated Approach to Identifying International Foodborne Norovirus Outbreaks1. Emerging Infectious Diseases, 2011, 17, 412-418.	2.0	35
56	On Being the Right Size: The Impact of Population Size and Stochastic Effects on the Evolution of Drug Resistance in Hospitals and the Community. PLoS Pathogens, 2011, 7, e1001334.	2.1	35
57	Increases in Condomless Sex in the Swiss HIV Cohort Study. Open Forum Infectious Diseases, 2015, 2, ofv077-ofv077.	0.4	35
58	Efficient microbial colony growth dynamics quantification with ColTapp, an automated image analysis application. Scientific Reports, 2020, 10, 16084.	1.6	35
59	Hepatitis C infection and the risk of non-liver-related morbidity and mortality in HIV-positive persons in the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2017, 64, ciw809.	2.9	34
60	Dually Active HIV/HBV Antiretrovirals as Protection Against Incident Hepatitis B Infections: Potential for Prophylaxis. Journal of Infectious Diseases, 2016, 214, 599-606.	1.9	34
61	Rational design of HIV-1 fluorescent hydrolysis probes considering phylogenetic variation and probe performance. Journal of Virological Methods, 2010, 165, 151-160.	1.0	33
62	Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 214.e1-214.e11.	0.6	32
63	High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virusâ€“coinfected Men Who Have Sex With Men. Clinical Infectious Diseases, 2019, 68, 569-576.	2.9	30
64	Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. Journal of Experimental Medicine, 2018, 215, 1589-1608.	4.2	29
65	Recombination and drug resistance in HIV: Population dynamics and stochasticity. Epidemics, 2009, 1, 58-69.	1.5	28
66	Assessment of Overlap of Phylogenetic Transmission Clusters and Communities in Simple Sexual Contact Networks: Applications to HIV-1. PLoS ONE, 2016, 11, e0148459.	1.1	28
67	Antibacterial Effects of Antiretrovirals, Potential Implications for Microbiome Studies in HIV. Antiviral Therapy, 2018, 23, 91-94.	0.6	28
68	Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. Open Forum Infectious Diseases, 2019, 6, ofz330.	0.4	28
69	Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants. Clinical Microbiology and Infection, 2016, 22, 191-200.	2.8	27
70	Viral Diversity Based on Next-Generation Sequencing of HIV-1 Provides Precise Estimates of Infection Recency and Time Since Infection. Journal of Infectious Diseases, 2019, 220, 254-265.	1.9	27
71	Quantifying Variation in Bacterial Reproductive Fitness: a High-Throughput Method. MSystems, 2021, 6, .	1.7	27
72	The Role of Recombination for the Coevolutionary Dynamics of HIV and the Immune Response. PLoS ONE, 2011, 6, e16052.	1.1	27

#	Article	IF	Citations
73	Assessing the impact of adherence to anti-retroviral therapy on treatment failure and resistance evolution in HIV. Journal of the Royal Society Interface, 2012, 9, 2309-2320.	1.5	26
74	Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfected men who have sex with men. Journal of Hepatology, 2016, 65, 26-32.	1.8	26
75	Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response. Journal of Clinical Investigation, 2022, 132, .	3.9	26
76	On the Causes of Selection for Recombination Underlying the Red Queen Hypothesis. American Naturalist, 2009, 174, S31-S42.	1.0	25
77	Social Meets Molecular: Combining Phylogenetic and Latent Class Analyses to Understand HIV-1 Transmission in Switzerland. American Journal of Epidemiology, 2014, 179, 1514-1525.	1.6	25
78	Mortality from suicide among people living with HIV and the general Swiss population: 1988â€2017. Journal of the International AIDS Society, 2019, 22, e25339.	1.2	24
79	Changing Trends in International Versus Domestic HCV Transmission in HIV-Positive Men Who Have Sex With Men: A Perspective for the Direct-Acting Antiviral Scale-Up Era. Journal of Infectious Diseases, 2019, 220, 91-99.	1.9	24
80	The role of epistasis on the evolution of recombination in hostâ€“parasite coevolution. Theoretical Population Biology, 2009, 75, 1-13.	0.5	23
81	Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitorâ€“Based Antiretroviral Treatment. Clinical Infectious Diseases, 2021, 73, e2134-e2141.	2.9	23
82	The Impact of Surgical Strategy and Rifampin on Treatment Outcome in Cutibacterium Periprosthetic Joint Infections. Clinical Infectious Diseases, 2021, 72, e1064-e1073.	2.9	22
83	Monocyte-derived macrophages exhibit distinct and more restricted HIV-1 integration site repertoire than CD4+ T cells. Scientific Reports, 2016, 6, 24157.	1.6	21
84	Large-scale inference of conjunctive Bayesian networks. Bioinformatics, 2016, 32, i727-i735.	1.8	21
85	The Role of Adherence and Retreatment in De Novo Emergence of MDR-TB. PLoS Computational Biology, 2016, 12, e1004749.	1.5	21
86	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. Clinical Infectious Diseases, 2016, 63, ciw519.	2.9	20
87	On the potential of a shortâ€term intensive intervention to interrupt HCV transmission in HIVâ€positive men who have sex with men: A mathematical modelling study. Journal of Viral Hepatitis, 2018, 25, 10-18.	1.0	20
88	Editorial Commentary: The Irreversibility of HIV Drug Resistance. Clinical Infectious Diseases, 2015, 61, 837-839.	2.9	19
89	Quantifying the impact of treatment history on plasmid-mediated resistance evolution in human gut microbiota. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 23106-23116.	3.3	19
90	Noninferiority of Simplified Dolutegravir Monotherapy Compared to Continued Combination Antiretroviral Therapy That Was Initiated During Primary Human Immunodeficiency Virus Infection: A Randomized, Controlled, Multisite, Open-label, Noninferiority Trial. Clinical Infectious Diseases, 2019, 69, 1489-1497.	2.9	19

#	Article	IF	Citations
91	Repeated Syphilis Episodes in HIV-Infected Men Who Have Sex With Men: A Multicenter Prospective Cohort Study on Risk Factors and the Potential Role of Syphilis Immunity. Open Forum Infectious Diseases, 2020, 7, ofaa019.	0.4	18
92	Rotating antibiotics does not minimize selection for resistance. Mathematical Biosciences and Engineering, 2010, 7, 919-922.	1.0	18
93	A Novel Acute Retroviral Syndrome Severity Score Predicts the Key Surrogate Markers for HIV-1 Disease Progression. PLoS ONE, 2014, 9, e114111.	1.1	17
94	A Direct Comparison of Two Densely Sampled HIV Epidemics: The UK and Switzerland. Scientific Reports, 2016, 6, 32251.	1.6	17
95	Development of a high-throughput bead based assay system to measure HIV-1 specific immune signatures in clinical samples. Journal of Immunological Methods, 2018, 454, 48-58.	0.6	17
96	Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study. Virus Evolution, 2018, 4, vey024.	2.2	17
97	Predicting the Evolution of Sex on Complex Fitness Landscapes. PLoS Computational Biology, 2009, 5, e1000510.	1.5	16
98	Higher Risk of Incident Hepatitis C Virus Coinfection Among Men Who Have Sex With Men, in Whom the HIV Genetic Bottleneck at Transmission Was Wide. Journal of Infectious Diseases, 2014, 210, 1555-1561.	1.9	16
99	Assessing the need for a preâ€exposure prophylaxis programme using the social media app GrindrÂ®. HIV Medicine, 2017, 18, 772-776.	1.0	16
100	Parent-offspring regression to estimate the heritability of an HIV-1 trait in a realistic setup. Retrovirology, 2017, 14, 33.	0.9	16
101	Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis. ELife, 2017, 6, .	2.8	16
102	Low prevalence of transmitted HIV-1 drug resistance detected by a dried blood spot (DBS)-based next-generation sequencing (NGS) method in newly diagnosed individuals in Cameroon in the years 2015â€“16. Journal of Antimicrobial Chemotherapy, 2018, 73, 1917-1929.	1.3	16
103	Phylodynamics on local sexual contact networks. PLoS Computational Biology, 2017, 13, e1005448.	1.5	16
104	Modeling the effect of HIV coinfection on clearance and sustained virologic response during treatment for hepatitis C virus. Epidemics, 2015, 12, 1-10.	1.5	15
105	Genotypic Resistance Tests Sequences Reveal the Role of Marginalized Populations in HIV-1 Transmission in Switzerland. Scientific Reports, 2016, 6, 27580.	1.6	15
106	Impact of screening and antiretroviral therapy on anal cancer incidence in HIV-positive MSM. Aids, 2017, 31, 1859-1866.	1.0	15
107	Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus coâ€infected HIV patients with cirrhosis. Journal of Viral Hepatitis, 2019, 26, 1224-1228.	1.0	15
108	Prevalence and risk factors of late presentation for HIV diagnosis and care in a tertiary referral centre in Switzerland. Swiss Medical Weekly, 2014, 144, w13961.	0.8	15

#	Article	IF	Citations
109	Postnatal retention in <scp>HIV</scp> care: insight from the <scp>S</scp>wiss <scp>HIV</scp> Cohort Study over a 15â€year observational period. HIV Medicine, 2016, 17, 280-288.	1.0	14
110	Absenteeism and presenteeism in healthcare workers due to respiratory illness. Infection Control and Hospital Epidemiology, 2021, 42, 268-273.	1.0	14
111	Sustained Effect on Hepatitis C Elimination Among Men Who Have Sex With Men in the Swiss HIV Cohort Study: A Systematic Re-Screening for Hepatitis C RNA Two Years Following a Nation-Wide Elimination Program. Clinical Infectious Diseases, 2022, 75, 1723-1731.	2.9	14
112	Estimating the Fitness Cost of Escape from HLA Presentation in HIV-1 Protease and Reverse Transcriptase. PLoS Computational Biology, 2012, 8, e1002525.	1.5	13
113	OUP accepted manuscript. Clinical Infectious Diseases, 2019, 68, 561-568.	2.9	13
114	Dietary Patterns and Physical Activity Correlate With Total Cholesterol Independently of Lipid-Lowering Drugs and Antiretroviral Therapy in Aging People Living With Human Immunodeficiency Virus. Open Forum Infectious Diseases, 2018, 5, ofy067.	0.4	12
115	Random forest machine learning algorithm predicts virologic outcomes among HIV infected adults in Lausanne, Switzerland using electronically monitored combined antiretroviral treatment adherence. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2021, 33, 530-536.	0.6	12
116	Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030. Swiss Medical Weekly, 2017, 147, w14543.	0.8	12
117	HIV drug resistance in sub-Saharan Africa: public health questions and the potential role of real-world data and mathematical modelling. Journal of Virus Eradication, 2018, 4, 55-58.	0.3	12
118	Modeling the measles paradox reveals the importance of cellular immunity in regulating viral clearance. PLoS Pathogens, 2018, 14, e1007493.	2.1	11
119	Bridging the gap between HIV epidemiology and antiretroviral resistance evolution: Modelling the spread of resistance in South Africa. PLoS Computational Biology, 2019, 15, e1007083.	1.5	11
120	Response to a sexual risk reduction intervention provided in combination with hepatitis C treatment by HIV/HCV co-infected men who have sex with men: a reflexive thematic analysis. BMC Infectious Diseases, 2021, 21, 319.	1.3	11
121	Identifying the drivers of multidrug-resistant Klebsiella pneumoniae at a European level. PLoS Computational Biology, 2021, 17, e1008446.	1.5	11
122	Genomic Surveillance of Vancomycin-Resistant Enterococcus faecium Reveals Spread of a Linear Plasmid Conferring a Nutrient Utilization Advantage. MBio, 2022, 13, e0377121.	1.8	11
123	No Effect of Pegylated Interferon-Î± on Total HIV-1 DNA Load in HIV-1/HCV Coinfected Patients. Journal of Infectious Diseases, 2018, 217, 1883-1888.	1.9	10
124	Phylogenetic Cluster Analysis Identifies Virological and Behavioral Drivers of Human Immunodeficiency Virus Transmission in Men Who Have Sex With Men. Clinical Infectious Diseases, 2021, 72, 2175-2183.	2.9	10
125	Similar Impact of CD8+ T Cell Responses on Early Virus Dynamics during SIV Infections of Rhesus Macaques and Sooty Mangabeys. PLoS Computational Biology, 2010, 6, e1000901.	1.5	9
126	Prescription of Postexposure Prophylaxis for HIV-1 in the Emergency Room: Correct Transmission Risk Assessment Remains Challenging. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 359-366.	0.9	9

#	Article	IF	Citations
127	Clusters of Sexual Behavior in Human Immunodeficiency Virusâ€“positive Men Who Have Sex With Men Reveal Highly Dissimilar Time Trends. Clinical Infectious Diseases, 2019, 70, 416-424.	2.9	9
128	Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland. Journal of Antimicrobial Chemotherapy, 2019, 74, 468-472.	1.3	9
129	Secondary attack rates from asymptomatic and symptomatic influenza virus shedders in hospitals: Results from the TransFLUas influenza transmission study. Infection Control and Hospital Epidemiology, 2022, 43, 312-318.	1.0	9
130	The impact of HCV therapy in a high HIV-HCV prevalence population: A modeling study on people who inject drugs in Ho Chi Minh City, Vietnam. PLoS ONE, 2017, 12, e0177195.	1.1	9
131	Distinct conformations of the HIV-1 V3 loop crown are targetable for broad neutralization. Nature Communications, 2021, 12, 6705.	5.8	9
132	Dolutegravir Monotherapy as Maintenance Strategy: A Meta-Analysis of Individual Participant Data From Randomized Controlled Trials. Open Forum Infectious Diseases, 2022, 9, .	0.4	9
133	Loss to follow-up of HIV-infected women after delivery: The Swiss HIV Cohort Study and the Swiss Mother and Child HIV Cohort Study. Journal of the International AIDS Society, 2014, 17, 19535.	1.2	8
134	The impact of vaccination on the breadth and magnitude of the antibody response to influenza A viruses in HIV-infected individuals. Aids, 2015, 29, 1803-1810.	1.0	8
135	The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis. Open Forum Infectious Diseases, 2018, 5, ofy078.	0.4	8
136	Spontaneous reactivation of latent HIV-1 promoters is linked to the cell cycle as revealed by a genetic-insulators-containing dual-fluorescence HIV-1-based vector. Scientific Reports, 2018, 8, 10204.	1.6	8
137	Screening HIV-positive men who have sex with men for hepatitis C re-infection risk: is a single question on condom-use enough? A sensitivity analysis. BMC Infectious Diseases, 2019, 19, 821.	1.3	8
138	Why do subâ€Saharan Africans present late for HIV care in Switzerland?. HIV Medicine, 2019, 20, 418-423.	1.0	8
139	Participation, retention and uptake in a multicentre preâ€exposure prophylaxis cohort using online, smartphoneâ€compatible data collection. HIV Medicine, 2022, 23, 146-158.	1.0	8
140	Quantification of within-patient Staphylococcus aureus phenotypic heterogeneity as a proxy for the presence of persisters across clinical presentations. Clinical Microbiology and Infection, 2022, 28, 1022.e1-1022.e7.	2.8	8
141	ON THE EVOLUTION OF SEXUAL REPRODUCTION IN HOSTS COEVOLVING WITH MULTIPLE PARASITES. Evolution; International Journal of Organic Evolution, 2010, 64, 1644-1656.	1.1	7
142	Telomere Length, Traditional Risk Factors, Factors Related to Human Immunodeficiency Virus (HIV) and Coronary Artery Disease Events in Swiss Persons Living With HIV. Clinical Infectious Diseases, 2021, 73, e2070-e2076.	2.9	7
143	Host Genomics of the HIV-1 Reservoir Size and Its Decay Rate During Suppressive Antiretroviral Treatment. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 517-524.	0.9	7
144	HIV-1 integration sites in CD4+ T-cells during primary, chronic, and late presentation of HIV-1 infection. JCI Insight, 2021, 6, .	2.3	7

#	Article	IF	Citations
145	Drivers of HIV-1 drug resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) in nine southern African countries: a modelling study. BMC Infectious Diseases, 2021, 21, 1042.	1.3	7
146	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. PLoS Medicine, 2020, 17, e1003397.	3.9	7
147	High Rates of Asymptomatic Mycoplasma genitalium Infections With High Proportion of Genotypic Resistance to First-Line Macrolide Treatment Among Men Who Have Sex With Men Enrolled in the Zurich Primary HIV Infection Study. Open Forum Infectious Diseases, 2022, 9, .	0.4	7
148	A method to estimate the size and characteristics of HIV-positive populations using an individual-based stochastic simulation model. Epidemiology, 2015, 27, 1.	1.2	6
149	Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study. Journal of Antimicrobial Chemotherapy, 2015, 70, dkv257.	1.3	6
150	Quantifying the drivers of <scp>HIV</scp> transmission and prevention in men who have sex with men: a population modelâ€based analysis in Switzerland. HIV Medicine, 2018, 19, 688-697.	1.0	6
151	The TransFLUas influenza transmission study in acute healthcare - recruitment rates and protocol adherence in healthcare workers and inpatients. BMC Infectious Diseases, 2019, 19, 446.	1.3	6
152	Lower Broadly Neutralizing Antibody Responses in Female Versus Male HIV-1 Infected Injecting Drug Users. Viruses, 2019, 11, 384.	1.5	6
153	A Systematic Phylogenetic Approach to Study the Interaction of HIV-1 With Coinfections, Noncommunicable Diseases, and Opportunistic Diseases. Journal of Infectious Diseases, 2019, 220, 244-253.	1.9	6
154	Implementation and evaluation of a care bundle for prevention of non-ventilator-associated hospital-acquired pneumonia (nvHAP) â€“ a mixed-methods study protocol for a hybrid type 2 effectiveness-implementation trial. BMC Infectious Diseases, 2020, 20, 603.	1.3	6
155	Assessing the potential impact of transmission during prolonged viral shedding on the effect of lockdown relaxation on COVID-19. PLoS Computational Biology, 2021, 17, e1008609.	1.5	6
156	Assessing the drivers of syphilis among men who have sex with men in Switzerland reveals a key impact of screening frequency: A modelling study. PLoS Computational Biology, 2021, 17, e1009529.	1.5	6
157	Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV. PLoS Biology, 2020, 18, e3000963.	2.6	6
158	Evaluation of the Predictive Potential of the Short Acute Retroviral Syndrome Severity Score for HIV-1 Disease Progression in Individuals With Acute HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, e114-e117.	0.9	5
159	Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART. Nature Communications, 2020, 11, 5542.	5.8	5
160	Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: A Prospective Multicenter Cohort Study. Journal of Infectious Diseases, 2020, 224, 1198-1208.	1.9	5
161	Coronary Artery Diseaseâ€“Associated and Longevity-Associated Polygenic Risk Scores for Prediction of Coronary Artery Disease Events in Persons Living With Human Immunodeficiency Virus: The Swiss HIV Cohort Study. Clinical Infectious Diseases, 2021, 73, 1597-1604.	2.9	5
162	Increasing Frequency and Transmission of HIV-1 Non-B Subtypes Among Men Who Have Sex With Men in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 2022, 225, 306-316.	1.9	5

#	Article	IF	Citations
163	Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis. Journal of Clinical Epidemiology, 2022, 148, 135-145.	2.4	5
164	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. Journal of Antimicrobial Chemotherapy, 2016, 71, 1352-1360.	1.3	4
165	From Intracellular Traffic to a Novel Class of Driven Lattice Gas Models. , 2007, , 205-222.		4
166	Decreasing Incidence and Determinants of Bacterial Pneumonia in People With HIV: The Swiss HIV Cohort Study. Journal of Infectious Diseases, 2022, 225, 1592-1600.	1.9	4
167	Estimating the dynamics and dependencies of accumulating mutations with applications to HIV drug resistance. Biostatistics, 2015, 16, 713-726.	0.9	3
168	Reply to correspondence â€˜Conserved signatures indicate HIV-1 transmission is under strong selection and thus is not a â€œstochasticâ€•processâ€™ by Gonzalez et al., Retrovirology 2017. Retrovirology, 2017, 14, 14.	0.9	3
169	Can Directionality of HIV Transmission be Predicted by Next-Generation Sequencing Data?. Journal of Infectious Diseases, 2018, 220, 1393-1395.	1.9	3
170	Incidental Findings on Coronary Computed Tomography Angiography in Human Immunodeficiency Virus (HIV)-Positive and HIV-Negative Persons. Open Forum Infectious Diseases, 2018, 5, ofy084.	0.4	3
171	Self-reported Neurocognitive Impairment in People Living With Human Immunodeficiency Virus (HIV): Characterizing Clusters of Patients With Similar Changes in Self-reported Neurocognitive Impairment, 2013â€“2017, in the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2020, 71, 637-644.	2.9	3
172	HCV Genetic Diversity Can Be Used to Infer Infection Recency and Time since Infection. Viruses, 2020, 12, 1241.	1.5	3
173	Immunophenotypic characterization of TCR Î³Î´ T cells and MAIT cells in HIV-infected individuals developing Hodgkinâ€™s lymphoma. Infectious Agents and Cancer, 2021, 16, 24.	1.2	3
174	Systematic screening of viral and human genetic variation identifies antiretroviral resistance and immune escape link. ELife, 2021, 10, .	2.8	3
175	Differences Between Infectious Disease Events in First Liver Transplant Versus Retransplantation in the Swiss Transplant Cohort Study. Liver Transplantation, 2021, 27, 1283-1290.	1.3	3
176	Identifying and Characterizing Trans Women in the Swiss HIV Cohort Study as an Epidemiologically Distinct Risk Group. Clinical Infectious Diseases, 2022, 74, 1468-1475.	2.9	3
177	Early off-label treatment during pandemics? A dilemma. Swiss Medical Weekly, 2020, 150, w20281.	0.8	3
178	Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over >17 Years. Journal of Infectious Diseases, 2022, 225, 1581-1591.	1.9	3
179	Impact of Latent Tuberculosis on Diabetes. Journal of Infectious Diseases, 2022, 225, 2229-2234.	1.9	3
180	A systematic molecular epidemiology screen reveals numerous HIV-1 superinfections in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 2022, , .	1.9	3

#	Article	IF	Citations
181	Mining for pairs: shared clinic visit dates identify steady <scp>HIV</scp>â€positive partnerships. HIV Medicine, 2017, 18, 667-676.	1.0	2
182	Data linkage to evaluate the long-term risk of HIV infection in individuals seeking post-exposure prophylaxis. Nature Communications, 2021, 12, 1219.	5.8	2
183	Impact of Delaying Antiretroviral Treatment During Primary Human Immunodeficiency Virus Infection on Telomere Length. Journal of Infectious Diseases, 2021, , .	1.9	2
184	Comparing mutational pathways to lopinavir resistance in HIV-1 subtypes B versus C. PLoS Computational Biology, 2021, 17, e1008363.	1.5	2
185	Using longitudinally sampled viral nucleotide sequences to characterize the drivers of HIVâ€1 transmission. HIV Medicine, 2021, 22, 346-359.	1.0	2
186	Differences in Social and Mental Well-Being of Long-Term Survivors among People who Inject Drugs and Other Participants in the Swiss HIV Cohort Study: 1980â€“2018. Antiviral Therapy, 2020, 25, 43-54.	0.6	2
187	The Interplay Between Replication Capacity of HIV-1 and Surrogate Markers of Disease. Journal of Infectious Diseases, 2022, 226, 1057-1068.	1.9	2
188	An Approach to Quantifying the Interaction between Behavioral and Transmission Clusters. Viruses, 2022, 14, 784.	1.5	2
189	Quantification of transgene expression in GSH AAVS1 with a novel CRISPR/Cas9-based approach reveals high transcriptional variation. Molecular Therapy - Methods and Clinical Development, 2022, 26, 107-118.	1.8	2
190	On the role of resonance in drug failure under HIV treatment interruption. Theoretical Biology and Medical Modelling, 2013, 10, 44.	2.1	1
191	Phylogenetic estimation of the viral fitness landscape of HIV-1 set-point viral load. Virus Evolution, 2022, 8, veac022.	2.2	1
192	HIV Transmission Chains Exhibit Greater HLA-B Homogeneity Than Randomly Expected. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 508-515.	0.9	0
193	Emergence of Human Immunodeficiency Virus-1 Drug Resistance During the 3-Month World Health Organization-Recommended Enhanced Adherence Counseling Period in the CART-1 Cohort Study. Open Forum Infectious Diseases, 2021, 8, ofab046.	0.4	0
194	Nonlinear mixed-effects models for HIV viral load trajectories before and after antiretroviral therapy interruption, incorporating left censoring. Statistical Communications in Infectious Diseases, 2022, 14, .	0.2	0
195	Similar but different: Integrated phylogenetic analysis of Austrian and Swiss HIV-1 sequences reveal differences in transmission patterns of the local HIV-1 epidemics. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, Publish Ahead of Print, .	0.9	0
196	Impact of an electronic alert on prescription patterns of meropenem, voriconazole and caspofungin. BMC Infectious Diseases, 2021, 21, 1263.	1.3	0
197	Title is missing!. , 2020, 18, e3000963.		0
198	Title is missing!. , 2020, 18, e3000963.		0

#	Article	IF	Citations
199	Title is missing!. , 2020, 18, e3000963.		0
200	Title is missing!. , 2020, 18, e3000963.		0
201	Title is missing!. , 2020, 18, e3000963.		0
202	Title is missing!. , 2020, 18, e3000963.		0
203	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0
204	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0
205	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0
206	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0